Max Rosett Sells 60,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 60,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Max Rosett also recently made the following trade(s):

• On Thursday, April 2nd, Max Rosett sold 65,000 shares of Immunome stock. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00.

Immunome Trading Up 3.5%

NASDAQ:IMNM traded up $0.62 during trading hours on Wednesday, reaching $18.53. 1,419,601 shares of the company were exchanged, compared to its average volume of 1,357,784. The stock’s 50-day moving average is $21.62 and its 200-day moving average is $21.70. The firm has a market cap of $2.10 billion, a PE ratio of -7.79 and a beta of 2.04. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, research analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research report on Tuesday, April 21st. Truist Financial boosted their price target on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Finally, Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. purchased a new position in Immunome in the third quarter worth approximately $39,000. KBC Group NV purchased a new position in shares of Immunome during the 1st quarter worth $60,000. BNP Paribas Financial Markets grew its holdings in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. Strs Ohio purchased a new position in shares of Immunome during the 4th quarter worth $64,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.